[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-on-chronic-hepatic-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-on-chronic-hepatic-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100441607","the-effects-of-double-plasma-molecular-adsorption-system-in-acute-on-chronic-liver-failure-patients-100441607",false,"NCT05030571","The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients","Inclusion Criteria:\n\n1. Age 18 or more\n2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the study of the liver (APASL) criteria\n3. Admitted to intensive care unit\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Received steroid treatment\n3. Expected dead within 24 hour\n4. WBC \\\u003C 500\u002Fmm3\n5. Allergy to DPMAS\n6. History of organ transplant\n7. Terminal illness with do not resuscitation order","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","Acute liver failure patients posed high mortality rate despite receiving standard therapy. The severity and mortality even higher in patients with underlying liver disease. Acute liver failure cause hyperinflammatory response in early stage and immunoparalysis in later stage. The surge of proinflammatory cytokines leads to multiorgan failure and more liver injury. Subsequent immunoparalysis may lead to lethal secondary infections.\n\nLiver support system had been used in acute and acute ontop chronic liver disease for last several decades. Double plasma molecular adsorption system (DPMAS) is one of the promising non-biological liver support system that have been extensively investigated in acute ontop chronic liver failure from hepatits B viral. DPMAS circuit consist of BS330 (bilirubin adsorber) and HA330 (Cytokines adsorber). Thus, DPMAS can also remove various cytokines. The effect of DPMAS on immune function in these patients has not been explored.\n\nRecent randomized controlled trial by Srisawat et al. demonstrated improvement of mHLA-DR in septic shock patients who received polymyxin B extracorporeal therapy compare to control arm. Since liver failure show change of immunological profile resemble to sepsis. Investigators proposed that removal of toxic liver toxins and lethal cytokines by DPMAS will improve immunological profiles in acute ontop chronic liver failure patients.\n\nInvestigators plan to conduct a randomized controlled trial in acute ontop chronic liver failure patients who admitted to intensive care unit. Investigators plan to compare the immunomodulatory effects of DPMAS with standard treatments.",[25,26],"Acute-On-Chronic Liver Failure","Acute on Chronic Hepatic Failure",[28,25,29,30],"Hemoperfusion","Cytokine adsorbant therapy","HA-330","RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":35},"2021-01-01",{"date":39,"type":19},"2027-04-01",{"name":41,"class":42},"Chulalongkorn University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100345145","comparison-of-inflammatory-profiles-and-regenerative-potential-in-alcoholic-liver-disease-100345145","NCT03773887","Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease","TargetOH","Inclusion Criteria:\n\n* group A: patients with acute alcoholic hepatitis\n* Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to admission (\\> 60 g per day for men and\\> 40 g per day for women)\n* Moderate elevation of transaminases (less than 500 U \u002F L) with a typical ASAT \u002F ALAT ratio of 2: 1\n* Bilirubin\\> 50 mg \u002F l\n* Absence of autoimmune liver disease (ANA \\\u003C1\u002F80, AML \\\u003C1\u002F80, LKM1 neg, AAM neg)\n* Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative HBsAg, negative HCV PCR)\n* Patients with other acute complications than alcoholic hepatitis may be included (eg, digestive hemorrhage, acute renal failure, infection, etc.)\n* Because there is no validated noninvasive tool for the diagnosis of alcoholic hepatitis, histological confirmation is required in all patients (preferably by transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the following histological characteristics: Hepatocellular lesions (ballooning, Mallory body)\u002F Inflammatory infiltrate with polymorphonuclear neutrophils\n* group B1: patients with alcoholic cirrhosis\n* Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments (www.has-sante.fr)\n* group B2: patients free from chronic liver disease\n* Justification of blood and liver sampling for the management of a pathology other than chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy liver)\n\nExclusion Criteria:\n\n* For groups A and B1:\n* Patients with hepatocellular carcinoma of progressive non-hepatic cancer\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy\n* for group B2:\n* Alcoholic liver disease\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy","70 Years",{"count":53,"type":19},450,[22],"The main objective of this study is the comparison of the profile of the pro-inflammatory cytokines at the patients suffering from an alcoholic hepatitis to that of two groups witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic liver disease",[57,26],"Liver Diseases","2026-05-20",{"date":60,"type":35},"2026-05-22",{"date":62,"type":35},"2014-12-25",{"date":64,"type":19},"2027-09",{"name":66,"class":42},"University Hospital, Lille",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":77,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100515319","phase-1-the-safety-tolerability-and-efficacy-study-of-hepacure-in-chinese-subjects-with-acute-on-chronic-liver-failure-100515319","NCT05989958","The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure","A Multicenter, Randomized, Controlled, Open-Label Phase 1\u002F2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HepaCure Plus DPMAS Versus DPMAS Alone in Chinese Subjects with Acute-On-Chronic Liver Failure","Inclusion Criteria:\n\n1. Able to communicate effectively with investigators and sign the informed consent form (ICF) voluntarily.\n2. Age: ≥ 18 years and ≤ 65 years.\n3. Body weight: ≥ 40kg;\n4. Met the criteria of ACLF in the early and middle stages in screening period (Guidelines for the Diagnosis and Treatment of Liverfilture (2018 Edition)): base on chronic liver disease, acute jaundice deepened and coagulation dysfunction caused by various inducements, manifested as extreme fatigue, with obvious gastrointestinal symptoms such as anorexia, vomiting, abdominal distention, etc; Progressive deepening of jaundice, serum TBil ≥ 171 μmol\u002FL or increase ≥ 17.1 μmol\u002FL daily or ≥10 × upper limit of normal value; with bleeding tendencies or manifestations (bleeding spots or ecchymosis), or 20%\\\u003CPTA ≤ 40% (or 1.5 ≤ INR\\\u003C2.6), and other reasons excluded.\n\nExclusion Criteria:\n\n1. Subjects with primary or metastatic liver cancer.\n2. Subjects with severe esophageal\u002Fgastric varices and high risk of bleeding, with positive red signs, or with previous active bleeding, as indicated by gastroscopy or imaging examination results.\n3. Serum creatinine was greater than 132.6 μmol\u002FL.\n4. Subjects with serious uncontrolled infections, including sepsis, septic shock, severe pneumonia (refers to the diagnostic criteria of the American Society of Infectious Diseases\u002FAmerican Thoracic Society for adult severe pneumonia in 2007), abdominal infection (exist Peritonitis manifestations or white blood cells in ascites\\>0.1 × 10 9\u002FL after reasonable antibiotic treatment), etc;","65 Years",{"count":76,"type":19},92,[78,79],"PHASE1","PHASE2","This is a multicenter, randomized, controlled, open-label phase 1\u002F2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure（ACLF）.\n\nPhase 1 is a multicenter, open label study to evaluate the safety and tolerability of single dose and multiple doses of HepaCure with different treatment duration plus DPMAS in ACLF subjects respectively.\n\nPhase 2 is a multicenter, randomized and controlled open label study to evaluate the efficacy, safety and tolerability of HepaCure plus DPMAS and LPE in ACLF subjects",[26,82,83],"Liver Failure","Hepatitis","2025-02-21",{"date":86,"type":35},"2025-02-25",{"date":88,"type":35},"2023-09-22",{"date":90,"type":19},"2026-09",{"name":92,"class":93},"Hexaell Biotech Co., Ltd.","INDUSTRY"]